Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
Ardelyx (ARDX) insider ownership update: Chief Medical Officer Edward R. Conner filed an initial statement of beneficial ownership. He reports 302,260 shares of Common Stock (footnoted as RSUs that settle one-for-one upon vesting) held directly.
He also holds a stock option for 463,268 shares of Common Stock at an exercise price of $5.21, with an expiration date of 08/08/2035. Vesting is scheduled so that 25% vests on 08/08/2026, and the remainder vests in 36 equal monthly installments, subject to continued service. The filing was made by one reporting person in the capacity of Chief Medical Officer.
Ardelyx (ARDX) insider James Parker Brady filed an initial statement of beneficial ownership. He reports 166,000 shares of Common Stock (including RSUs that settle one share per RSU upon vesting) and a stock option for 250,000 shares at $3.93 expiring on 06/03/2035.
The option vests 25% on 06/03/2026, with the balance vesting in 36 equal monthly installments, subject to continued service. Brady serves as Chief Human Resources Officer. The event date is 06/18/2025.
Ardelyx appointed Sue Hohenleitner as chief financial officer and principal financial officer, effective November 4, 2025. She brings senior finance experience from Johnson & Johnson, including serving as CFO of J&J Innovative Medicine North America.
Her compensation includes an annual base salary of $550,000 and a target bonus equal to 45% of base salary, pro‑rated for fiscal 2025. Upon her employment commencement on October 13, 2025, she received a sign‑on bonus of $180,000 and a housing consideration payment of $150,000. Equity awards granted on October 13, 2025 comprise an option to purchase 578,104 shares at an exercise price of $5.01 per share, vesting over four years (25% after one year, then monthly over 36 months), and 146,896 restricted stock units vesting 25% on the first quarterly vest date after the one‑year anniversary, then quarterly over three years. The company plans to enter into its standard indemnification and change‑in‑control severance agreements with her.
Laura A. Williams, Chief Patient Officer of Ardelyx, Inc. (ARDX), reported multiple transactions on 08/26/2025 executed pursuant to a written plan under Rule 10b5-1. The filing shows an acquisition of 50,000 shares of common stock at $0.99 and two dispositions totaling 80,000 shares sold at a weighted average price of $6.121 (trades ranged $6.04–$6.20). Following these transactions, Ms. Williams beneficially owned 366,322 shares of common stock. The Form 4 also discloses a stock option with a $0.99 exercise price covering 50,000 shares that vests in 48 equal monthly installments beginning January 6, 2022, and expires January 6, 2032. The form is signed by an attorney-in-fact for Ms. Williams.
Mike Kelliher, Chief Business Officer and Director of Ardelyx, Inc. (ARDX), reported a sale of common stock on 08/21/2025. An automatic sell-to-cover executed upon the vesting of restricted stock units resulted in the disposition of 5,417 shares at $5.9317 per share to satisfy tax withholding. After the transaction, Kelliher beneficially owned 276,741 shares, reported as direct ownership. The Form 4 was filed as a single reporting person and signed by an attorney-in-fact on 08/28/2025.
Ardelyx, Inc. (ARDX) filed a Form 144 notifying the proposed sale of 80,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $484,800.00 and an approximate sale date of 08/26/2025 on NASDAQ. The filing shows the securities were acquired partly by exercise of stock options on 08/26/2025 (50,000 shares, paid in cash) and partly as restricted stock units on 02/19/2024 (30,000 shares). The filer also reported a prior sale of 6,261 shares on 08/21/2025 generating gross proceeds of $37,138.37. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1 notice language.
Laura A. Williams, listed as Chief Patient Officer and a director of Ardelyx, Inc. (ARDX), reported a non-derivative sale on 08/21/2025. The filing shows 6,261 shares of common stock were sold at $5.9317 per share under code S(1). The sale was executed pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units to cover withholding taxes. After the transaction, Williams is reported to beneficially own 396,322 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Ardelyx, Inc. insider Justin A. Renz, the company's Chief Financial Officer, reported a sale of 7,037 shares of ARDX common stock on 08/21/2025 at an average price of $5.9317 per share. After the transaction, Mr. Renz beneficially owned 409,052 shares. The filing states the sale was an automatic "sell-to-cover" triggered when restricted stock units vested, executed solely to satisfy withholding tax obligations. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Michael G. Raab, President & CEO and Director of Ardelyx, Inc. (ARDX), reported a sale of 45,687 shares of common stock on 08/21/2025 at a price of $5.9317 per share. The filing states the sale was an automatic sell-to-cover to satisfy tax withholding upon vesting of restricted stock units. After the transaction, Mr. Raab beneficially owns 1,502,250 shares directly, plus 24,364 shares held in his living trust and 1,000 shares held in trusts for his children. No derivative transactions are reported in this Form 4. The form is signed by an attorney-in-fact and dated 08/25/2025.
Elizabeth A. Grammer, Chief Legal and Administrative Officer of Ardelyx, Inc. (ARDX), reported the disposition of 5,841 shares of the issuer's common stock on 08/21/2025. The sale was executed at $5.9317 per share under code S(1) and is described as an automatic sell-to-cover tied to the vesting of restricted stock units to satisfy withholding taxes. Following the transaction, Ms. Grammer beneficially owned 305,890 shares, held directly. The form is signed by the reporting person on 08/25/2025.